FDA grants Orphan Drug Designation to Omeros' OMS721 for treatment of HSCT-TMA
Omeros announced OMS721 has received orphan drug designation from the FDA for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. October 23, 2018